Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
vTv Therapeutics Inc. (VTVT) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/11/2023 8-K Quarterly results
Docs: "vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update"
07/20/2023 8-K Quarterly results
06/08/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update"
04/26/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/06/2023 10-K Annual Report for the period ended December 31, 2022
03/06/2023 8-K Quarterly results
Docs: "Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update"
02/01/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics HIGH POINT, N.C., February 1, 2023 -- vTv Therapeutics Inc. , a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes , today announced the appointment of Elizabeth Keiley as Executive Vice President and General Counsel, effective immediately. “We welcome Betzy to vTv. Her years of legal expertise and deep experience in life sciences will be valuable to the vTv team,” said Paul Sekhri, President and Chief Executive Officer of vTv Therapeutics. “Her decades of experience in both private practice and corporate settings make her an ideal fit for this position. I am confident that we will benefit from her contributions and look forwar..."
01/06/2023 8-K Investor presentation
Docs: "THE STATEMENTS MADE IN THIS PRESENTATION MAY INCLUDE FORWARD"
12/23/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
12/13/2022 8-K Quarterly results
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
Docs: "Agreements with CinRx Pharma and"
08/23/2022 SC 13G Medpace Investors, LLC reports a 5.2% stake in vTv Therapeutics Inc.
08/15/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/15/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
07/27/2022 8-K Quarterly results
07/25/2022 8-K Quarterly results
07/15/2022 8-K Quarterly results
06/10/2022 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
06/03/2022 8-K Quarterly results
06/01/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
06/01/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
05/12/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/02/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/15/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/05/2022 10-K/A Annual Report for the period ended December 31, 2021 [amend]
04/05/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/29/2022 10-K Annual Report for the period ended December 31, 2021
03/29/2022 8-K Quarterly results
Docs: "vTv Therapeutics Announces 2021 fourth Quarter and Full Year Financial Results and Provides Corporate Update"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy